Glucophage XR

Glucophage XR is the extended-release formulation of metformin hydrochloride (originally developed by Merck). It utilizes a specialized dual-hydrophilic polymer matrix system (GELSHIELD technology) that hydrates in the gastrointestinal tract to form a gel layer. As the drug slowly diffuses through this matrix, active metformin is released steadily over several hours. This extended-release profile allows for convenient once-daily administration with significantly reduced peak-to-trough blood plasma fluctuations and fewer gastrointestinal side effects compared to immediate-release metformin.

Like standard metformin, Glucophage XR activates AMP-activated protein kinase (AMPK) to:

• Suppress Hepatic Gluconeogenesis: Reduce excess glucose production in the liver.

• Enhance Peripheral Insulin Sensitivity: Increase glucose uptake and utilization by skeletal muscle and adipose tissues.

• Delay Intestinal Glucose Absorption: Slow down the rate of glucose uptake across the intestinal mucosa.

Primary Medical Indications

Glucophage XR is indicated for adult and pediatric populations (aged 10 years and older, depending on regional approvals) for managing blood glucose levels in:

• Type 2 Diabetes Mellitus: First-line oral monotherapy or combination therapy (with sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or insulin) to improve glycemic control alongside diet and exercise.

• Prediabetes Management: Off-label or approved indication in patients with impaired fasting glucose or impaired glucose tolerance to delay progression to type 2 diabetes.

• Polycystic Ovary Syndrome (PCOS): Off-label use to target insulin resistance, lower circulating androgen levels, and restore ovulatory cycles in women with PCOS.

• Switching from Immediate-Release Metformin: Indicated for patients experiencing GI intolerance (diarrhea, bloating, nausea) on standard metformin IR.

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Do Not Crush or Chew: The GELSHIELD matrix relies on an intact tablet structure. Crushing or chewing destroys the extended-release mechanism, leading to rapid drug release and increased risk of adverse effects.

• Boxed Warning for Lactic Acidosis: A rare but serious metabolic complication. Risk increases in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 $\text{m}^2$), acute cardiac failure, severe hepatic insufficiency, or excessive alcohol intake.

• Ghost Tablet Shell Excretion: Patients should be advised that the insoluble tablet matrix (the “ghost shell”) may occasionally pass through the digestive tract intact and appear in the stool; this is normal and does not affect drug efficacy.

• Iodinated Contrast Studies: Temporarily withhold Glucophage XR before or at the time of procedures using intravascular iodinated contrast in patients with eGFR between 30 and 60 mL/min/1.73 $\text{m}^2$ or with hepatic risk factors.

• Vitamin $B_{12}$ Monitoring: Long-term administration can decrease intestinal absorption of vitamin $B_{12}$. Annual monitoring of hematologic parameters and serum $B_{12}$ levels is recommended.